Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Benigne Prostatahyperplasie und Urolithiasis

Benign prostatic hyperplasia and urolithiasis


Die Volkskrankheiten benigne Hyperplasie und Urolithiasis bilden zwei Pfeiler des urologischen Diagnostik- und Behandlungsspektrums. Dieser Artikel enthält eine Übersicht über die bedeutsamsten und praxisrelevanten Publikationen der letzten Jahre. Insbesondere wird die Verbindung dieser beiden Erkrankungen mit den kardiovaskulären Risikofaktoren wie z. B. Adipositas und Diabetes mellitus immer deutlicher. Die möglichen diagnostischen Verfahren und Therapien werden sich in Zukunft daran orientieren.


Benign prostatic hyperplasia and urolithiasis are widespread diseases and are two of the most important elements of the urological therapeutic spectrum. This article gives an overview of the most interesting publications on the subject from the past few years. Particularly the link with cardiovascular risk factors like obesity and diabetes appears to be stronger than supposed. The diagnostic and therapeutic tools of the future will be developed with respect to this.

This is a preview of subscription content, log in to check access.


  1. 1.

    Karatas OF, Bayrak O, Cimentepe E, Unal D (2009) An insidious risk factor for cardiovascular disease: Benign prostatic hyperplasia. Int J Cardiol 131, doi:10.1016/j.ijcard.2009.03.099

  2. 2.

    Parsons JK, Sarma AV, McVary K, Wei JT (2009) Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol Vol 182:27–31

  3. 3.

    Sarma AV, Parsons JK, McVary K, Wei JT (2009) Diabates and prostatic hyperplasia/Lower urinary tract symoptoms – what do we know? J Urol Vol 182:32–37

  4. 4.

    Robert G, Descazeaud A, Nicolaïew N et al (2009) Inflammation in benign prostatic hyperplasia: a 282 patients‘ immunohistochemical analysis. Prostate 69(16):1774–1780

  5. 5.

    Oelke M, Höfner K, Jonas U et al (2007) Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol 52(3):827–834

  6. 6.

    Barkin J, Guimarães M, Jacobi G et al (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44(4):461–466

  7. 7.

    Jeong YB, Kwon KS, Kim SD, Kim HJ (2009) Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. Urology 73(4):802–806

  8. 8.

    Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57(1):123–131

  9. 9.

    John H, Bucher C, Engel N et al (2009) Preperitoneal robotic prostate adenomectomy. Urology 73(4):811–815

  10. 10.

    Desai MM, Fareed K, Berger AK et al (2010) Single-port transvesical enucleation of the prostate: a clinical report of 34 cases. BJU Int 105(9):1296–1300

  11. 11.

    Mamoulakis C, Ubbink DT, Rosette JJ de la (2009) Bipolar versus Monopolar Transurethral Resection of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol 56:798–809

  12. 12.

    Bach T, Wendt-Nordahl G, Michel MS et al (2009) Feasibility and efficacy of Thulium: YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol 27(4):541–545

  13. 13.

    Szlauer R, Götschl R, Razmaria A et al (2009) Endoscopic vaporesection of the prostate using the continuous-wave 2-microm thulium laser: outcome and demonstration of the surgical technique. Eur Urol 55(2):368–375

  14. 14.

    Mattioli S, Muñoz R, Recasens R et al (2008) Treatment of benign prostatic hyperplasia with the Revolix laser. Arch Esp Urol 61(9):1037–1043

  15. 15.

    Xia SJ, Zhuo J, Sun XW et al (2008) Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol 53(2):382–389

  16. 16.

    Ruszat R, Seitz M, Wyler SF et al (2009) Prospective single-centre comparison of 120-W diode-pumped solid-state high-intensity system laser vaporization of the prostate and 200-W high-intensive diode-laser ablation of the prostate for treating benign prostatic hyperplasia. BJU Int 104(6):820–825

  17. 17.

    Chen CH, Chiang PH, Chuang YC et al (2010) Preliminary results of prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-W high-intensity diode laser. Urology 75(3):658–663

  18. 18.

    Brisinda G, Cadeddu F, Vanella S et al (2009) Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 73(1):90–94

  19. 19.

    Carnevale FC, Antunes AA, Motta Leal Filho JM da et al (2010) Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol 33(2):355–361

  20. 20.

    Hesse A, Brändle E, Wilbert D et al (2003) Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000. Eur Urol 44(6):709–713

  21. 21.

    Boyce CJ, Pickhardt PJ, Lawrence EM et al (2010) Prevalence of urolithiasis in asymptomatic adults: objective determination using low dose noncontrast computerized tomography. J Urol 183(3):1017–1021

  22. 22.

    Semins MJ, Shore AD, Makary MA et al (2010) The association of increasing body mass index and kidney stone disease. J Urol 183(2):571–575

  23. 23.

    Yü T, Gutman AB (1967) Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med 67(6):1133–1148

  24. 24.

    Daudon M, Lacour B, Jungers P (2005) High prevalence of uric acid calculi in diabetic stone formers. Nephrol Dial Transplant 20(2):468–469

  25. 25.

    Siener R, Glatz S, Nicolay C, Hesse A (2004) The role of overweight and obesity in calcium oxalate stone formation. Obes Res 12(1):106–113

  26. 26.

    Lieske JC (2009) Gastric bypass procedures and renal calculi – how should we counsel patients and bariatric surgeons? J Urol 182(5):2105–2106

  27. 27.

    Yuruk E, Binbay M, Sari E et al (2010) A prospective, randomized trial of management for asymptomatic lower pole calculi. J Urol 183(4):1424–1428

  28. 28.

    Al-Ansari A, Al-Naimi A, Alobaidy A et al (2010) Efficacy of tamsulosin in the management of lower ureteral stones: a randomized double-blind placebo-controlled study of 100 patients. Urology 75(1):4–7

  29. 29.

    Brede C, Hollingsworth JM, Faerber GJ et al (2010) Medical expulsive therapy for ureteral calculi in the real world: targeted education increases use and improves patient outcome. J Urol 183(2):585–589

  30. 30.

    Salem HK (2009) A prospective randomized study comparing shock wave lithotripsy and semirigid ureteroscopy for the management of proximal ureteral calculi. Urology 74(6):1216–1221

Download references


Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Correspondence to Prof. Dr. M.S. Michel.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Krombach, P., Michel, M. Benigne Prostatahyperplasie und Urolithiasis. Urologe 49, 149–153 (2010).

Download citation


  • Benigne Prostatahyperplasie
  • Urolithiasis
  • Metabolisches Syndrom
  • Koronarsyndrom


  • Benign prostatic hyperplasia
  • Urolithiasis
  • Metabolic syndrome
  • Acute coronary syndrome